Jasper Therapeutics, Inc. (JSPR) is a clinical-stage biotechnology company developing briquilimab, an anti-CD117 monoclonal antibody aimed at mast cell–driven diseases, principally chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The company recently completed a 1-for-30 reverse stock split, effective November 6, 2026, to restore compliance with Nasdaq's $1.00 minimum bid price rule. Because most analyst price targets were published before the split, the central target used here is the pre-split analyst mean converted to a post-split basis, rounded to $240.
The $240 average analyst price target is not a figure analysts published in post-split terms; it is a mechanical conversion. Before the November 2026 reverse split, eight verifiable targets were in force, spanning roughly $1.50 (UBS, Neutral) to $20 (H.C. Wainwright, Buy), with a calculated mean near $7.94. Multiplying by the 1-for-30 ratio yields a post-split mean of about $238, rounded to $240, and a range of approximately $45 to $600.
Views diverge sharply. Bulls — including H.C. Wainwright, Rodman & Renshaw ($17), and Evercore ISI ($7, Outperform) — cite briquilimab's encouraging CSU data and competitive profile. Cautious firms have repeatedly cut targets: BTIG and Citizens JMP lowered to $7 and $6, RBC Capital to $3, and Piper Sandler initiated at $2, while William Blair and TD Cowen hold non-Buy ratings. UBS's $1.50 sits at the low end. This dispersion shows the analyst consensus is far from uniform, and the mean should not be read as a guarantee.
Shortly after the reverse split, shares traded around $16, with Yahoo Finance reporting a close near $16.37. Reaching $240 would require a gain of roughly 1,370% from that level — a move best described as very large even by early-stage biotech standards. The path would almost certainly depend on briquilimab progressing through late-stage clinical trials toward regulatory submissions for CSU and CIndU, timelines that analysts have already pushed to roughly 2030 and 2031, respectively. Because Jasper is pre-revenue and posts consistent net losses, the price forecast hinges on clinical and regulatory catalysts rather than near-term earnings.
Positive CSU efficacy and safety data for briquilimab is the central bull case; Rodman & Renshaw's initiation highlighted strong efficacy and a favorable profile. A clearer path to approval, a partnership or licensing deal, or a substantial financing that extends the cash runway could all improve the market outlook. The reverse split itself, by restoring Nasdaq compliance and lifting the share price above $1, may support liquidity and institutional eligibility, though it does not change fundamental value.
The biggest obstacles are financial and clinical. Jasper's cash position is limited, and analysts have repeatedly flagged the potential need for additional capital — raising the risk of dilutive financings. The company paused its asthma and severe combined immunodeficiency (SCID) programs to focus resources on CSU and CIndU, concentrating risk in a narrower pipeline. Launches are not expected until around 2030–2031, and a clinical setback, a delayed trial, or a financing shortfall could compress the stock forecast materially. Reverse splits also frequently see renewed selling pressure.
On a split-adjusted basis, JSPR's 52-week range spans roughly $9.45 to $72.60. The stock trades near the lower end of that range, and the post-split level near $16 acts as an early reference point. A sustained move above the $20 area would represent the first meaningful step away from its recent lows, while the adjusted 52-week high near $72 remains a distant, psychologically significant level. Any serious discussion of $240 would require the stock to clear multiple, far higher zones with no established support level or resistance level in between, given how sharply the price has declined.
Analyst targets generally reflect a 12-month research horizon, but for Jasper they appear to embed a longer-term, probability-weighted view of briquilimab's value, given launch expectations near 2030. Investors should monitor quarterly earnings (the Q3 2026 report was expected around mid-November), cash balances and any financing announcements, briquilimab trial readouts and regulatory updates, and any analyst target revisions now that shares trade on a post-split basis. Nasdaq listing compliance and insider transactions are also worth watching.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap such as JSPR, this type of automated monitoring can help traders spot shifting trends and manage positions more efficiently. Investors interested in systematic, data-driven idea generation may find these signals a useful complement to fundamental research.
Can JSPR reach $240? That target is the analyst mean mechanically adjusted for a 1-for-30 reverse split, and it sits more than 1,300% above the recent price — an extraordinary implied move reflecting how far the stock has fallen rather than a near-term forecast. The bull case rests on briquilimab's CSU potential, while the bear case centers on a thin cash runway, dilution risk, delayed timelines, and pipeline concentration. With analyst targets ranging from roughly $45 to $600 on a post-split basis, there is no meaningful analyst consensus on valuation, and reaching $240 would require a clinical and financing outcome far beyond what current trading prices reflect.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, JSPR has been loosely correlated with AUPH. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if JSPR jumps, then AUPH could also see price increases.
| Ticker / NAME | Correlation To JSPR | 1D Price Change % | ||
|---|---|---|---|---|
| JSPR | 100% | -9.90% | ||
| AUPH - JSPR | 44% Loosely correlated | -1.93% | ||
| IMRX - JSPR | 40% Loosely correlated | +5.48% | ||
| FRMM - JSPR | 38% Loosely correlated | -2.08% | ||
| NXTC - JSPR | 37% Loosely correlated | -4.63% | ||
| BNTC - JSPR | 35% Loosely correlated | -5.98% | ||
More | ||||